Harnessing the natural machinery of the lysosome

Draupnir Bio is a spin out company, from Aarhus University, Denmark and the Max-Planck Society, Germany. Backed by a syndicate of leading European investors – Gilde Healthcare Partners, Inkef Capital, Novo Seeds, MP Healthcare Venture Management, and EIFO – Draupnir is based in Copenhagen, with research operations centered in Aarhus, Denmark.

We are establishing ourselves at the forefront of extracellular targeted protein degradation, which is enabled for multi-modality degraders. Our focus is on building a new paradigm for the effective and safe clearance of protein aggregates using sortilin-based lysosome targeting chimeras (SORTACs) against proteinopaties in areas of high unmet medical need.

Targeted protein degradation (TPD) is a rapidly emerging field in drug development, exploiting a cell’s own destruction machinery to tackle disease-causing proteins that have historically been highly challenging to target with conventional therapies.

This has the potential to offer patients new treatment options across multiple indications and yet first-generation approaches are exclusively limited to intracellular targets, leaving extracellular and membrane-bound proteins – 40% of the human proteome – untouched.

At Draupnir, we are extending the potential of protein degradation to target extracellular and membrane-bound proteins in a pioneering approach using our novel and differentiated, proprietary technology platform which targets lysosome receptors, and has the potential to revolutionise the field of TPD.

Our team at Draupnir Bio is driven by a deep commitment to scientific excellence and the desire to bring innovative therapies to patients in need.